A Randomized, Double-blind Phase 3 Study to Compare the Immunogenicity of Clinical Trial Material of an Ad26.RSV.preF-based Vaccine for Phase 3 With Clinical Trial Material Representative of Phase 2b in Adults Aged 60 to 75 Years

ClinicalTrials.gov processed this data on October 11, 2023. Link to the current ClinicalTrials.gov record.

Recruitment Status

COMPLETED - HAS RESULTS
 (See Contacts and Locations)
Verified October 2023 by Janssen Vaccines & Prevention B.V.

Sponsor

Janssen Vaccines & Prevention B.V.

Information Provided by (Responsible Party)

Janssen Vaccines & Prevention B.V.

Clinicaltrials.gov Identifier

NCT05083585
Other Study ID Numbers: CR109065
First Submitted: October 7, 2021
First Posted: October 19, 2021
Results First Posted: September 11, 2023
Last Update Posted: October 13, 2023
Last Verified: October 2023
History of Changes

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

Not Provided
Condition or Disease Intervention/Treatment
  • Respiratory Syncytial Virus Prevention
  • Biological: Ad26.RSV.preF-based vaccine

Study Design

Study TypeInterventional
Actual Enrollment250 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingDouble
Primary PurposeOther
Official TitleA Randomized, Double-blind Phase 3 Study to Compare the Immunogenicity of Clinical Trial Material of an Ad26.RSV.preF-based Vaccine for Phase 3 With Clinical Trial Material Representative of Phase 2b in Adults Aged 60 to 75 Years
Study Start DateOctober 8, 2021
Actual Primary Completion DateMarch 7, 2022
Actual Study Completion DateSeptember 22, 2022

Groups and Cohorts

Group/ CohortIntervention/ Treatment
  • Group 1: Phase 3 Clinical Trial Material (CTM)
    • Participants will receive a single intramuscular (IM) injection of adenovirus serotype 26 (Ad26). respiratory syncytial virus (RSV). prefusion conformation-stabilized F protein (preF)-based vaccine on Day 1, which is a Phase 3 CTM.
  • Biological: Ad26.RSV.preF-based vaccine
    • Ad26.RSV.preF-based vaccine will be administered as a single intramuscular injection.
  • Group 2: Phase 2b CTM
    • Participants will receive a single IM injection of Ad26.RSV.preF-based vaccine on Day 1, which is a Phase 2b CTM.
  • Biological: Ad26.RSV.preF-based vaccine
    • Ad26.RSV.preF-based vaccine will be administered as a single intramuscular injection.

Outcome Measures

Primary Outcome Measures

  1. Geometric Mean Titers (GMTs) of Prefusion F-protein (preF) Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA) 14 Days Post Vaccination [14 days post vaccination on Day 1 (Day 15)]
    GMTs of pre-F antibodies as assessed by ELISA at 14 days post administration of Ad26/protein preF RSV based vaccine were reported.

Secondary Outcome Measures

  1. Number of Participants With Solicited Local Adverse Events (AEs) for 7 Days Post Vaccination [Up to Day 7 post vaccination on Day 1 (up to Day 8)]
    Number of participants with solicited local AEs 7 days post vaccination on Day 1 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs were precisely defined events that participants were specifically asked about and which were noted by participants in the diary. Solicited local AEs that included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, were used to assess the reactogenicity of the study vaccine and were pre-defined local (injection site).
  2. Number of Participants With Solicited Systemic AEs for 7 Days Post Vaccination [Up to Day 7 post vaccination on Day 1 (up to Day 8)]
    Number of participants with solicited systemic AEs 7 days post vaccination on Day 1 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited systemic events included events such as fatigue, headache, nausea, and myalgia, for which participants were specifically questioned and which were noted by participants in their participant diary for 7 days post vaccination (day of vaccination and the subsequent 7 days).
  3. Number of Participants With Unsolicited AEs for 28 Days Post Vaccination [Up to Day 28 post vaccination on Day 1 (up to Day 29)]
    Number of participants with unsolicited AEs 28 days post vaccination on Day 1 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs were all AEs for which the participant was not specifically questioned in the participant diary.
  4. Number of Participants With Serious Adverse Events (SAEs) Until 6 Months Post Vaccination [From Day 1 up to 6 months post vaccination on Day 1 (up to Day 183)]
    Number of participants with SAEs until 6 months post vaccination on Day 1 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.
  5. Number of Participants With Adverse Event of Special Interests (AESIs) Until 6 Months Post Vaccination [From Day 1 up to 6 months post vaccination on Day 1 (up to Day 183)]
    Number of participants with AESIs until 6 months post vaccination on Day 1 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Thrombosis with thrombocytopenia syndrome (TTS) was considered as an AESI.
  6. Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers at 14 Days Post Vaccination [14 days post vaccination on Day 1 (Day 15)]
    RSV A2 strain neutralizing antibody titers of the vaccine-induced immune response was assessed through virus neutralization assay at 14 days post administration of Ad26/protein preF RSV based vaccine were expressed as 50 percent (%) inhibitory concentration (IC50) units.

Eligibility Criteria

Ages Eligible for Study 60 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study All
Accepts Healthy Volunteers Yes
Inclusion Criteria
  • Willing and able to adhere to the prohibitions and restrictions specified in the protocol
  • Before randomization, a participant must be postmenopausal (postmenopausal state is defined as no menses for 12 months without an alternative medical cause); and not intending to conceive by any methods
  • In the investigator's clinical judgment, participant must be in stable health at the time of vaccination. Participants may have underlying illnesses such as hypertension, congestive heart failure, chronic obstructive pulmonary disease, type 2 diabetes, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms and signs are stable at the time of vaccination, and these conditions receive routine follow-up by the participant's healthcare provider. Participants will be included on the basis of medical history, and vital signs performed between informed consent form (ICF) signature and vaccination
  • Must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study
  • From the time of vaccination through 3 months after vaccination, agrees not to donate blood
Exclusion Criteria
  • Known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine)
  • Abnormal function of the immune system resulting from clinical condition or medication
  • History of acute polyneuropathy (example, Guillain-BarrĂ© syndrome) or chronic idiopathic demyelinating polyneuropathy
  • History of thrombosis with thrombocytopenia syndrome (TTS) or heparin-induced thrombocytopenia and thrombosis (HITT)
  • Has had major surgery (per the investigator's judgment) within 4 weeks before administration of the study vaccine or will not have recovered from surgery per the investigator's judgment at time of vaccination

Contacts and Locations

Sponsors and Collaborators Janssen Vaccines & Prevention B.V.
Locations
  • Artemis Institute for Clinical Research | San Diego, California, United States, 92103
  • Optimal Research | San Diego, California, United States, 92108
  • Accel Research Sites | Lakeland, Florida, United States, 33803
  • Optimal Research | Melbourne, Florida, United States, 32934
  • Pharmax Research Clinic Inc | Miami, Florida, United States, 33126
  • Research Institute of South Florida Inc | Miami, Florida, United States, 33173
  • Progressive Medical Research | Port Orange, Florida, United States, 32127
  • Meridian Clinical Research, LLC | Cincinnati, Ohio, United States, 45219
  • Tekton Research Inc. | San Antonio, Texas, United States, 78229
Investigators

    Study Documents (Full Text)

    More Information

    Additional Relevant MeSH Terms